LATEST MANUSCRIPTS IN NAR Cancer
- Henning Ummethum, Jiayi Li, Michael Lisby, Vibe H Oestergaard. Emerging roles of the CIP2A-TopBP1 complex in genome integrity. NAR cancer. 2023, 5 (4): zcad052
Cited : 0Read More - Ran Li, Dongyi Wan, Junnan Liang, Huifang Liang, Haohao Huang, Ganxun Li. Pan-cancer analysis of promoter activity quantitative trait loci. NAR cancer. 2023, 5 (4): zcad053Cited : 0Read More
- Emmanuelle Hodara, Aubree Mades, Lisa Swartz, Maheen Iqbal, Tong Xu, Daniel Bsteh, Peggy J Farnham, Suhn K Rhie, Amir Goldkorn. mA epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer. NAR cancer. 2023, 5 (4): zcad054Cited : 1Read More
- Ha X Dang, Debanjan Saha, Reyka Jayasinghe, Sidi Zhao, Emily Coonrod, Jacqueline Mudd, S Peter Goedegebuure, Ryan Fields, Li Ding, Christopher A Maher. Single-cell transcriptomics reveals long noncoding RNAs associated with tumor biology and the microenvironment in pancreatic cancer. NAR cancer. 2023, 5 (4): zcad055Cited : 0Read More
- Cosmin Tudose, Jonathan Bond, Colm J Ryan. Gene essentiality in cancer is better predicted by mRNA abundance than by gene regulatory network-inferred activity. NAR cancer. 2023, 5 (4): zcad056Cited : 1Read More
- Jana Slyskova, Alba Muniesa-Vargas, Israel Tojal da Silva, Rodrigo Drummond, Jiyeong Park, David Häckes, Isabella Poetsch, Cristina Ribeiro-Silva, Amandine Moretton, Petra Heffeter, Orlando D Schärer, Wim Vermeulen, Hannes Lans, Joanna I Loizou. Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy. NAR cancer. 2023, 5 (4): zcad057Cited : 2Read More
- Si Hoi Kou, Jiaheng Li, Benjamin Tam, Huijun Lei, Bojin Zhao, Fengxia Xiao, San Ming Wang. germline pathogenic variants in modern humans were likely originated during recent human history. NAR cancer. 2023, 5 (3): zcad025Cited : 6Read More
- Meng Wang, Prethish Sreenivas, Benjamin D Sunkel, Long Wang, Myron Ignatius, Benjamin Z Stanton. The 3D chromatin landscape of rhabdomyosarcoma. NAR cancer. 2023, 5 (3): zcad028Cited : 6Read More
- Jan Benada, Daria Bulanova, Violette Azzoni, Valdemaras Petrosius, Saba Ghazanfar, Krister Wennerberg, Claus Storgaard Sørensen. Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma. NAR cancer. 2023, 5 (3): zcad029Cited : 8Read More
- Dylan Pelletier, Anne-Laure Chong, Mona Wu, Leora Witkowski, Sophie Albert, Nelly Sabbaghian, Marc R Fabian, William D Foulkes. DICER1 platform domain missense variants inhibit miRNA biogenesis and lead to tumor susceptibility. NAR cancer. 2023, 5 (3): zcad030Cited : 1Read More
- Junhong Guan, Guo-Min Li. DNA mismatch repair in cancer immunotherapy. NAR cancer. 2023, 5 (3): zcad031Cited : 9Read More
- Madhura R Pandkar, Adarsh Raveendran, Kajal Biswas, Srinivas Abhishek Mutnuru, Jharna Mishra, Atul Samaiya, Tyler Malys, Alexander Y Mitrophanov, Shyam K Sharan, Sanjeev Shukla. PKM2 dictates the poised chromatin state of promoter to enhance breast cancer progression. NAR cancer. 2023, 5 (3): zcad032Cited : 3Read More
- Juliet D Strauss, Zachary F Pursell. Replication DNA polymerases, genome instability and cancer therapies. NAR cancer. 2023, 5 (3): zcad033Cited : 6Read More
- Susan M Grimes, Heon Seok Kim, Sharmili Roy, Anuja Sathe, Carlos I Ayala, Xiangqi Bai, Alison F Almeda-Notestine, Sarah Haebe, Tanaya Shree, Ronald Levy, Billy T Lau, Hanlee P Ji. Single-cell multi-gene identification of somatic mutations and gene rearrangements in cancer. NAR cancer. 2023, 5 (3): zcad034Cited : 3Read More
- Daniel Croft, Puja Lodhia, Sofia Lourenco, Craig MacKay. Effectively utilizing publicly available databases for cancer target evaluation. NAR cancer. 2023, 5 (3): zcad035Cited : 3Read More
